✦ LIBER ✦

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders

✍ Scribed by Cervantes, F; Passamonti, F; Barosi, G

Book ID: 109886814
Publisher: Nature Publishing Group
Year: 2008
Tongue: English
Weight: 205 KB
Volume: 22
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2008.72

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

bcr/abl-Negative, Classic Myeloprolifera

bcr/abl-Negative, Classic Myeloproliferative Disorders: Diagnosis and Treatment

✍ Tefferi, Ayalew; Barbui, Tiziano 📂 Article 📅 2005 🏛 Mayo Clinic 🌐 English ⚖ 169 KB

Mutational analysis in BCR-ABL -negative

Mutational analysis in BCR-ABL -negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices

✍ Tefferi, Ayalew 📂 Article 📅 2010 🏛 Informa plc 🌐 English ⚖ 201 KB

Genetic analysis of chromosome 13 deleti

Genetic analysis of chromosome 13 deletions in BCR/ABL negative chronic myeloproliferative disorders

✍ Cristina Pastore; Josep Nomdedeu; Gisella Volpe; Angelo Guerrasio; Giovanna Rege 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

## Abstract Chromosomal deletions of band 13q14 occur recurrently in __BCR/ABL__ negative chronic myeloproliferative disorders (CMPD), including myelosclerosis with myeloid metaplasia (MMM), polycythemia vera (PV), essential thrombocythemia (ET), juvenile chronic myeloid leukemia (JCML), and the so

Biological Rationale and Clinical Use of

Biological Rationale and Clinical Use of Interferon in the Classical BCR-ABL-Negative Myeloproliferative Neoplasms

✍ Stein, Brady L.; Tiu, Ramon V. 📂 Article 📅 2013 🏛 Mary Ann Liebert 🌐 English ⚖ 308 KB

Pathogenetic insight and prognostic info

Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs)

✍ Reilly, J T 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 200 KB

PEG-IFN-α-2b therapy in BCR-ABL–negative

PEG-IFN-α-2b therapy in BCR-ABL–negative myeloproliferative disorders : Final Result of a Phase 2 Study

✍ Elias Jabbour; Hagop Kantarjian; Jorge Cortes; Deborah Thomas; Guillermo Garcia- 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB

## Abstract ## BACKGROUND. Interferon‐alpha (IFN‐α) has shown significant activity in the treatment of BCR‐ABL–negative myeloproliferative disorders (MPDs), particularly essential thrombocythemia (ET) and polycythemia vera (PV). PEG‐IFN‐α‐2b is a pegylated IFN‐α‐2b with a significant advantage ove